Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years.

Trial Profile

Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2016

At a glance

  • Drugs AS03A; Influenza A virus vaccine-H5N1
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Nov 2011 Actual end date (June 2008) added as reported by ClinicalTrials.gov
    • 29 Sep 2011 NCT00449670 reports patients number as 1181.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top